Beyond BRCA and HRD

October 4, 2022

Ovarian cancer treatment continues to evolve and some women benefit from new therapy options in addition to gold standard surgery and frontline chemotherapy. But what if you’re not a BRCA mutation carrier or your doctor thinks your cancer is not HRD (homologous recombination deficient)? Women for whom PARP inhibitors are not indicated, haven't worked, or stopped working, want to know what therapies are in the pipeline for us! Join Dr. Elise Kohn, Head of Gynecologic Cancer Therapeutics at the National Cancer Institute (NCI) Cancer Therapy Evaluation Program, for a conversational program that will focus on the ovarian cancer treatment landscape beyond BRCA and HRD.

This is SHARE's eighth annual Joan Sommer Educational Program. Joan was a nurse diagnosed with Stage IV ovarian cancer at the birth of her third child. She lived with ovarian cancer for 22 years. With her natural wry humor and intelligence, Joan and her family inspired and supported the SHARE community. The Sommer legacy continues.

Key takeaways from webinar viewers:

Learned more about PARP inhibitor pros/cons.

There are trials for recurrent ovarian cancer that do not hinge on whether you have a BRCA mutation or HRD.

New treatment options are currently being tested extensively.

Each patient is unique and should ask questions about what studies show about the risks/potential benefits of a particular drug or therapy.